Please login to the form below

Not currently logged in
Email:
Password:

peginterferon beta-1a

This page shows the latest peginterferon beta-1a news and features for those working in and with pharma, biotech and healthcare.

New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU

New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU

Plegridy (peginterferon beta-1a) is a long-acting treatment for RRMS in which interferon beta-1a – the active ingredient in Biogen's Avonex (interferon beta-1a) – is pegylated to make the ... drug last longer in the body than other beta interferons.

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....